Beihai Gofar Chuanshan Biological (600538.SH) announced the performance for the first three quarters, with a net loss of 20.88 million yuan.

Zhitong Finance · Oct 29 23:29

Beihai Gofar Chuanshan Biological (600538.SH) disclosed its third quarter report for 2024, achieving revenue in the first three quarters...

Zhixin Finance and Economics APP News, Beihai Gofar Chuanshan Biological (600538.SH) disclosed its third quarter report for 2024, with revenue of 0.263 billion yuan in the first three quarters, a 6.99% year-on-year decrease. Net loss attributable to shareholders of the listed company was 20.8826 million yuan, and net loss after deducting non-recurring gains and losses attributable to shareholders of the listed company was 16.9508 million yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

国发股份(600538.SH)发布前三季度业绩 净亏损2088万元

Beihai Gofar Chuanshan Biological (600538.SH) announced the performance for the first three quarters, with a net loss of 20.88 million yuan.

Risk Disclaimer

Statement

国发股份(600538.SH)发布前三季度业绩净亏损2088万元